The impact of both CMRs and genetic risk for AD, such as apolipoprotein E‐ε4 (APOE4), are known to differ between males and females (Alqarni et al., 2021; Bretsky et al., 1999; Geerlings et al., 2010; Gerdts & Regitz‐Zagrosek, 2019; Neu et al., 2017; Schorr et al., 2018). Here, APOE is linked to Alzheimer disease.